For Bio Pharma
Implementation infrastructure and real-world evidence.
LiverTwin™ supports the commercial, medical, clinical, and evidence needs of MASH pharma companies.
Pharma companies need more than awareness campaigns. They need implementation infrastructure that helps real clinics run the MASH care pathway and create measurable evidence.
Patient finding & funnel creation
Identify high-risk patients from EHR, labs, metabolic risk, imaging reports, medication history, and prior non-invasive testing.
Site activation & workflow readiness
Help health systems standardize NIT completion, hepatology referral, baseline assessment, therapy readiness, and follow-up scheduling.
Therapy response monitoring
Track longitudinal signals across fibrosis risk, steatosis, liver enzymes, weight, HbA1c, lipids, adherence, comedications, and follow-up completion.
Real-world evidence generation
Create de-identified evidence on patient activation, testing completion, treatment persistence, response trajectories, care gaps, and outcomes.
For pharma, LiverTwin™ can become the bridge between therapy availability and real-world utilization.
Karyon Bio can help pharma partners move beyond "drug launch" into a measurable operating model: identify the patient, complete the workup, start the pathway, monitor response, support persistence, and document value.
An AI-powered MASH therapy-management layer built for pharma partnerships.
Scan routine care data to identify likely MASLD/MASH patients and prioritize F2+ risk.
Coordinate next-best non-invasive testing based on site capability and patient risk.
Summarize baseline risk, comorbidities, safety considerations, and prior testing.
Track changes in labs, imaging, NITs, metabolic status, adherence, and follow-up completion.
Flag missed testing, lost follow-up, inadequate response, and escalation needs.
Aggregate de-identified evidence for medical affairs, clinical development, and market access.
Therapy-aware, NIT-agnostic, and evidence-ready.
MASH therapy management will require multiple signals across time. LiverTwin integrates the clinical, diagnostic, medication, workflow, and outcomes data needed to support pharma partners.
Surfaces high-risk F2+ candidates and missed-care populations across participating clinical sites.
Shows whether clinical sites are completing NITs, referrals, baseline documentation, and therapy-readiness workflows.
Tracks whether patients are improving, stabilizing, or failing to respond across liver, metabolic, imaging, and workflow signals.
Generates structured evidence on eligibility, persistence, response, appropriate use, and care-pathway impact.
Helps identify cohorts, support registry design, track longitudinal endpoints, and prepare real-world datasets.
Where LiverTwin™ fits across pharma functions.
LiverTwin can support multiple pharma stakeholders with a common evidence and workflow layer, while maintaining clinical governance and physician oversight.
Medical Affairs
Support disease education, pathway development, site engagement, and evidence generation around diagnosis, therapy readiness, monitoring, and care gaps.
Clinical Development
Identify eligible cohorts, support registry programs, observe longitudinal endpoints, and study therapy response in real clinical settings.
Market Access
Produce evidence on appropriate use, response, persistence, resource utilization, follow-up completion, and potential cost-offset narratives.
Commercial Operations
Understand site readiness, patient funnel leakage, treatment pathway bottlenecks, and opportunities for clinical workflow support.
HEOR and RWE
Generate de-identified, longitudinal datasets that connect patient risk, testing, therapy exposure, response, adherence, and outcomes.
Patient Access
Identify gaps in testing, referral, follow-up, and persistence that prevent eligible patients from benefiting from therapy.
A practical path from pilot deployments to pharma-grade evidence.
Karyon Bio can help pharma partners move from retrospective insights to prospective pathway execution, therapy monitoring, and multi-site real-world evidence programs.
Karyon Bio is not another single-point diagnostic. It is a pharma enablement platform for the MASH treatment era.
The MASH market will need multiple therapies, multiple non-invasive tests, and multiple stakeholder workflows. LiverTwin™ provides the connective intelligence layer that helps pharma partners understand who is eligible, who is treated, who responds, who does not, and what care gaps remain.
Evidence-first · Therapy-aware · NIT-agnostic